Skip to main content
. 2018 Aug 18;21(1):26–36. doi: 10.1093/neuonc/noy137

Table 1.

Summary of the proposed RANO response criteria for meningiomas

Criterion CR PR MR SD PD
Target lesions None ≥50% decrease in area relative to baseline ≥25% and <50% decrease in area relative to baseline <25% decrease relative to baseline but <25% increase in area relative to nadir ≥25% increase in area relative to nadir*
Nontarget lesions None Stable or improved Stable or improved Stable or improved Unequivocal PD*
New lesion(s)** None None None None Present*
Corticosteroids None Stable or decreased Stable or decreased Stable or decreased NA+
Clinical status Stable or improved Stable or improved Stable or improved Stable or improved Worse*
Requirement for response All All All All Any+

NA, not applicable.

*Progression occurs when this criterion is met.

**New lesion = new lesion not present on prior scans and visible in at least 2 projections. If a new lesion is equivocal, for example because of its small size, continued therapy may be considered, and follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan showing the new lesion. For immunotherapy-based approaches, new lesions alone do not define progression (see “Guidance in the case of new lesion(s) while on immunotherapy”).

+Increase in corticosteroids alone will not be taken into account in determining progression in the absence of persistent clinical deterioration.